BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

568 related articles for article (PubMed ID: 27859259)

  • 1. Vessel co-option is common in human lung metastases and mediates resistance to anti-angiogenic therapy in preclinical lung metastasis models.
    Bridgeman VL; Vermeulen PB; Foo S; Bilecz A; Daley F; Kostaras E; Nathan MR; Wan E; Frentzas S; Schweiger T; Hegedus B; Hoetzenecker K; Renyi-Vamos F; Kuczynski EA; Vasudev NS; Larkin J; Gore M; Dvorak HF; Paku S; Kerbel RS; Dome B; Reynolds AR
    J Pathol; 2017 Feb; 241(3):362-374. PubMed ID: 27859259
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vessel co-option and resistance to anti-angiogenic therapy.
    Kuczynski EA; Reynolds AR
    Angiogenesis; 2020 Feb; 23(1):55-74. PubMed ID: 31865479
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mechanism of tumour vascularization in experimental lung metastases.
    Szabo V; Bugyik E; Dezso K; Ecker N; Nagy P; Timar J; Tovari J; Laszlo V; Bridgeman VL; Wan E; Frentzas S; Vermeulen PB; Reynolds AR; Dome B; Paku S
    J Pathol; 2015 Feb; 235(3):384-96. PubMed ID: 25319725
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vessel co-option mediates resistance to anti-angiogenic therapy in liver metastases.
    Frentzas S; Simoneau E; Bridgeman VL; Vermeulen PB; Foo S; Kostaras E; Nathan M; Wotherspoon A; Gao ZH; Shi Y; Van den Eynden G; Daley F; Peckitt C; Tan X; Salman A; Lazaris A; Gazinska P; Berg TJ; Eltahir Z; Ritsma L; Van Rheenen J; Khashper A; Brown G; Nystrom H; Sund M; Van Laere S; Loyer E; Dirix L; Cunningham D; Metrakos P; Reynolds AR
    Nat Med; 2016 Nov; 22(11):1294-1302. PubMed ID: 27748747
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Different Forms of Tumor Vascularization and Their Clinical Implications Focusing on Vessel Co-option in Colorectal Cancer Liver Metastases.
    Haas G; Fan S; Ghadimi M; De Oliveira T; Conradi LC
    Front Cell Dev Biol; 2021; 9():612774. PubMed ID: 33912554
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Mechanism of tumour vascularisation in experimental lung metastases].
    Szabó V
    Magy Onkol; 2020 Mar; 64(1):73-75. PubMed ID: 32181766
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Angiogenesis in NSCLC: is vessel co-option the trunk that sustains the branches?
    Coelho AL; Gomes MP; Catarino RJ; Rolfo C; Lopes AM; Medeiros RM; Araújo AM
    Oncotarget; 2017 Jun; 8(24):39795-39804. PubMed ID: 26950275
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pathological features of vessel co-option versus sprouting angiogenesis.
    Latacz E; Caspani E; Barnhill R; Lugassy C; Verhoef C; Grünhagen D; Van Laere S; Fernández Moro C; Gerling M; Dirix M; Dirix LY; Vermeulen PB
    Angiogenesis; 2020 Feb; 23(1):43-54. PubMed ID: 31655928
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vessel co-option in primary human tumors and metastases: an obstacle to effective anti-angiogenic treatment?
    Donnem T; Hu J; Ferguson M; Adighibe O; Snell C; Harris AL; Gatter KC; Pezzella F
    Cancer Med; 2013 Aug; 2(4):427-36. PubMed ID: 24156015
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neutrophils expressing lysyl oxidase-like 4 protein are present in colorectal cancer liver metastases resistant to anti-angiogenic therapy.
    Palmieri V; Lazaris A; Mayer TZ; Petrillo SK; Alamri H; Rada M; Jarrouj G; Park WY; Gao ZH; McDonald PP; Metrakos P
    J Pathol; 2020 Jun; 251(2):213-223. PubMed ID: 32297656
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tumor microenvironment conditions that favor vessel co-option in colorectal cancer liver metastases: A theoretical model.
    Rada M; Lazaris A; Kapelanski-Lamoureux A; Mayer TZ; Metrakos P
    Semin Cancer Biol; 2021 Jun; 71():52-64. PubMed ID: 32920126
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Apelin inhibition prevents resistance and metastasis associated with anti-angiogenic therapy.
    Uribesalgo I; Hoffmann D; Zhang Y; Kavirayani A; Lazovic J; Berta J; Novatchkova M; Pai TP; Wimmer RA; László V; Schramek D; Karim R; Tortola L; Deswal S; Haas L; Zuber J; Szűcs M; Kuba K; Dome B; Cao Y; Haubner BJ; Penninger JM
    EMBO Mol Med; 2019 Aug; 11(8):e9266. PubMed ID: 31267692
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular differences of angiogenic versus vessel co-opting colorectal cancer liver metastases at single-cell resolution.
    Fleischer JR; Schmitt AM; Haas G; Xu X; Zeisberg EM; Bohnenberger H; Küffer S; Teuwen LA; Karras PJ; Beißbarth T; Bleckmann A; Planque M; Fendt SM; Vermeulen P; Ghadimi M; Kalucka J; De Oliveira T; Conradi LC
    Mol Cancer; 2023 Jan; 22(1):17. PubMed ID: 36691028
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Generation of vessel co-option lung metastases mouse models for single-cell isolation of metastases-derived cells and endothelial cells.
    Cuypers A; Teuwen LA; Bridgeman VL; de Rooij LPMH; Eelen G; Dewerchin M; Cantelmo AR; Kalucka J; Bouché A; Vinckier S; Carton A; Manderveld A; Vermeulen PB; Reynolds AR; Carmeliet P
    STAR Protoc; 2022 Dec; 3(4):101691. PubMed ID: 36173713
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Changes in tumour vessel density upon treatment with anti-angiogenic agents: relationship with response and resistance to therapy.
    Vasudev NS; Goh V; Juttla JK; Thompson VL; Larkin JM; Gore M; Nathan PD; Reynolds AR
    Br J Cancer; 2013 Sep; 109(5):1230-42. PubMed ID: 23922108
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vessel co-option in cancer.
    Kuczynski EA; Vermeulen PB; Pezzella F; Kerbel RS; Reynolds AR
    Nat Rev Clin Oncol; 2019 Aug; 16(8):469-493. PubMed ID: 30816337
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti-VEGF antibody therapy does not promote metastasis in genetically engineered mouse tumour models.
    Singh M; Couto SS; Forrest WF; Lima A; Cheng JH; Molina R; Long JE; Hamilton P; McNutt A; Kasman I; Nannini MA; Reslan HB; Cao TC; Ho CC; Barck KH; Carano RA; Foreman O; Eastham-Anderson J; Jubb AM; Ferrara N; Johnson L
    J Pathol; 2012 Aug; 227(4):417-30. PubMed ID: 22611036
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HGF/c-Met pathway is one of the mediators of sunitinib-induced tumor cell type-dependent metastasis.
    Shojaei F; Simmons BH; Lee JH; Lappin PB; Christensen JG
    Cancer Lett; 2012 Jul; 320(1):48-55. PubMed ID: 22269210
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Angiogenesis of gastrointestinal tumours and their metastases--a target for intervention?
    Garcea G; Lloyd TD; Gescher A; Dennison AR; Steward WP; Berry DP
    Eur J Cancer; 2004 Jun; 40(9):1302-13. PubMed ID: 15177488
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Investigation of the Lack of Angiogenesis in the Formation of Lymph Node Metastases.
    Jeong HS; Jones D; Liao S; Wattson DA; Cui CH; Duda DG; Willett CG; Jain RK; Padera TP
    J Natl Cancer Inst; 2015 Sep; 107(9):. PubMed ID: 26063793
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.